Get the Stockscreener App
0.41
6.61%
-0.029
After Hours:
.41
Helius Medical Technologies Inc stock is traded at $0.41, with a volume of 33,280.
It is down -6.61% in the last 24 hours and down -13.41% over the past month.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
See More
Previous Close:
$0.439
Open:
$0.4258
24h Volume:
33,280
Relative Volume:
0.01
Market Cap:
$2.49M
Revenue:
$502.00K
Net Income/Loss:
$-8.86M
P/E Ratio:
-0.0723
EPS:
-5.67
Net Cash Flow:
$-10.71M
1W Performance:
+2.47%
1M Performance:
-13.41%
6M Performance:
-22.57%
1Y Performance:
-92.76%
1-Day Range:
$0.405
$0.4258
1-Week Range:
$0.395
$0.4889
52-Week Range:
$0.373
$7.188
Helius Medical Technologies Inc Stock (HSDT) Company Profile
Name
Helius Medical Technologies Inc
Sector
Industry
Phone
215-944-6100
Address
642 NEWTOWN YARDLEY ROAD, NEWTOWN, PA
Compare HSDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSDT
Helius Medical Technologies Inc
|
0.41 | 2.49M | 502.00K | -8.86M | -10.71M | -5.67 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Helius Medical Technologies Inc Stock (HSDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-21 | Initiated | Noble Capital Markets | Outperform |
Helius Medical Technologies Inc Stock (HSDT) Latest News
Virtu Financial LLC Purchases New Shares in Helius Medical Technologies, Inc. (NASDAQ:HSDT) - Defense World
Helius Medical Unveils Revelation Neuro to Pioneer AI-Powered Neurorehabilitation - MSN
Helius Medical Creates Brain-Computer Interface Subsidiary - Medical Product Outsourcing
SEC Form 424B5 filed by Helius Medical Technologies Inc. - Quantisnow
Helius Medical Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Helius Medical Technologies Inc. (HSDT) reports earnings - Quartz
Chronic Traumatic Encephalopathy Pipeline 2025: MOA, ROA, - openPR.com
Helius Medical Technologies Inc expected to post a loss of 94 cents a shareEarnings Preview - TradingView
Chronic Traumatic Encephalopathy Treatment Market Size in 7MM - openPR.com
Helius Medical Technologies Reports Positive Preliminary Results from PoNSTEP Study - MSN
Helius Medical Technologies (HSDT) Expected to Announce Quarterly Earnings on Wednesday - The AM Reporter
Helius Medical Secures First Insurance Reimbursement for PoNS Device - MSN
Helius joins BCI landscape with new subsidiary - Yahoo
Helius Medical launches AI-driven BCI subsidiary - Investing.com Australia
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ('BCI”) Technology Private Subsidiary - The Manila Times
Helius Medical launches AI-driven BCI subsidiary By Investing.com - Investing.com UK
Helius Medical Technologies, Inc. Announces the - GlobeNewswire
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer ... - Bluefield Daily Telegraph
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - TradingView
Helius Medical's New AI Brain Interface Venture Aims to Transform Neurorehabilitation Without Surgery - StockTitan
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - The Manila Times
Helius Medical Technologies, Inc. Announces First - GlobeNewswire
Helius Medical announces first reimbursement for PoNS Device - TipRanks
Major Breakthrough: Anthem BCBS Approves $15,420 Payment for Helius Medical's PoNS Device - StockTitan
Helius Medical Technologies, Inc. (NASDAQ: HSDT) Featured in Coverage of the 37th Annual ROTH Conference - Financial Content
Helius Medical Tech Stock Price, Quotes and Forecasts | NASDAQ:HSDT - Benzinga
Helius Medical Technologies Moves Closer to Medicare Reimbursement, Expands Stroke Program - MSN
Neurology Devices Market Detailed In New Research Report 2025 | - openPR
Research Reports on BELLUS Health Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - ACCESS Newswire
Helius Medical faces Nasdaq delisting over bid price By Investing.com - Investing.com Canada
Helius Medical Technologies (NASDAQ:HSDT) Shares Down 5.8% – What’s Next? - Armenian Reporter
Helius Medical faces Nasdaq delisting over bid price - Investing.com
Helius Medical Technologies IncContinues Non-Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
Helius Medical Technologies (NASDAQ:HSDT) Trading Down 5.8% – Should You Sell? - Defense World
Enrollment for Helius Stroke Pivotal Study Exceeds Initial Target - Physical Therapy Products
PoNS therapy shows promise for MS gait deficits - MSN
PoNSTEP Study Confirms Long-Term Benefits of PoNS Therapy for MS Patients - MSN
Helius Medical Secures Funds Through Warrant Agreements - TipRanks
HSDTHelius Medical Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Helius Medical Surpasses Enrollment Target for Stroke Program - MSN
Helius Medical Technologies, Inc. Announces Exercise of - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - The Manila Times
Helius Medical Technologies, Inc. Announces First Clinical - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term ... - The Bakersfield Californian
Helius exceeds stroke study enrollment goals By Investing.com - Investing.com Australia
Helius Medical Technologies Inc Stock (HSDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):